← Leaderboards
Silvere M Van Der Maarel
Leiden University Medical Center
$3,630,501
Attributed
$3,986,063
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $583.7K · FY2007–19$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$3,986,063 · 7
By mechanism
P01$2,142,662 · 2
R21$1,843,401 · 5
Top collaborators
- Steven J Burden2 shared
Others in their field
Top investigators on “Genetic”
- Richard A Gibbs · Baylor College Of Medicine$577,061,667
- Eric S Lander · Whitehead Institute For Biomedical Res$560,806,052
- David R. Weir · University Of Michigan At Ann Arbor$322,225,557
- Richard K. Wilson · Washington University$316,685,275
- Lawrence Corey · Fred Hutchinson Cancer Center$312,182,347
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$302,429,647
Research focus
GeneticCellsD4z4Epigenetic ProcessMyoblastsChromatin StructureVariantFacioscapulohumeral Muscular DystrophyChromatinInsightPathogenesisBaseMutationRepressionEnhancersLeadMuscleGenesComplexCharacteristicsFunctional DisorderIn VitroMyopathyGenetic Transcription
Grant awards (21)
Project 1: Pathways and mechanisms repressing D4Z4 repeats$210,767
P01 · FY2019 · NS · contact PI
Project 1: Pathways and mechanisms repressing D4Z4 repeats$393,272
P01 · FY2018 · NS · contact PI
Project 1: Pathways and mechanisms repressing D4Z4 repeats$216,778
P01 · FY2017 · NS · contact PI
An Agonist Antibody to MuSK As A Theraputic For MuSK Myasthenia Gravis$346,875
R21 · FY2016 · NS
Project 1: Pathways and mechanisms repressing D4Z4 repeats$217,794
P01 · FY2016 · NS · contact PI
An Agonist Antibody to MuSK As A Theraputic For MuSK Myasthenia Gravis$364,250
R21 · FY2015 · NS
Project 1: Pathways and mechanisms repressing D4Z4 repeats$219,475
P01 · FY2015 · NS · contact PI
The Genetic and Epigenetic Basis for FSHD$168,030
P01 · FY2014 · NS · contact PI
The Genetic and Epigenetic Basis for FSHD$173,651
P01 · FY2013 · NS · contact PI
The Genetic and Epigenetic Basis for FSHD$176,228
P01 · FY2012 · NS · contact PI
The Genetic and Epigenetic Basis for FSHD$175,388
P01 · FY2011 · NS · contact PI
Identification of the gene defect underlying ICF2 syndrome$131,449
R21 · FY2011 · AI · contact PI
Clonal Isogenic and Immortalized FSHD Myoblasts with or without D4Z4 Contraction$120,736
R21 · FY2011 · AR · contact PI
The Genetic and Epigenetic Basis for FSHD$191,279
P01 · FY2010 · NS · contact PI
Identification of the gene defect underlying ICF2 syndrome$130,965
R21 · FY2010 · AI · contact PI
Clonal isogenic and immortalized FSHD myoblasts with or without D4Z4 contraction$121,492
R21 · FY2010 · AR · contact PI
FSHD as a Disorder of Impaired RNA Biogenesis$136,534
R21 · FY2008 · AR · contact PI
FSHD as a Disorder of Impaired RNA Biogenesis$116,100
R21 · FY2007 · AR · contact PI
Llama-derived phage display antibody arrays for FSHD$125,000
R21 · FY2003 · AR
Llama-derived phage display antibody arrays for FSHD$125,000
R21 · FY2002 · AR
Llama-derived phage display antibody arrays for FSHD$125,000
R21 · FY2001 · AR